Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics
Today's Latest Price: $5.69 USD
Dec 2 4:00pm Add ASMB to Watchlist Sign Up
ASMB Stock Summary The ratio of debt to operating expenses for Assembly Biosciences Inc is higher than it is for about just 10.02% of US stocks. As for revenue growth, note that ASMB's revenue has grown 454.77% over the past 12 months; that beats the revenue growth of 98.41% of US companies in our set. Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ASMB comes in at -74.54% -- higher than that of only 4.88% of stocks in our set. Stocks that are quantitatively similar to ASMB, based on their financial statements, market capitalization, and price volatility, are BLUE, APTX, NERV, CLLS, and NKTR. Visit ASMB's SEC page to see the company's official filings. To visit the company's web site, go to www.assemblybio.com.
ASMB Price/Volume Stats
Assembly Biosciences, Inc. (ASMB) Company Bio
Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.
ASMB Latest News Stream
All News Types
Debt Offering Downgrade Earnings Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Product News PT Raised Stock Offering Upgrade
Loading, please wait...
Latest ASMB News From Around the Web
Below are the latest news stories about Assembly Biosciences Inc that investors may wish to consider to help them evaluate ASMB as an investment opportunity.
Assembly Biosciences (ASMB) announces clinical data on lead HBV core inhibitor vebicorvir (ABI-H0731) and second-generation core inhibitor ABI-H2158. The results were virtually presented at the European Association for the Study of the Liver ((EASL)) Annual Meeting.Vebicorvir, combined with nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy in patients with HBeAg-negative chronic hepatitis...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company…
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer ...
-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China ---- Assembly receives $40 million…
BeiGene (BGNE) and Assembly Biosciences (ASMB) have announced a new collaboration in China for Assembly’s three clinical-stage core inhibitor candidates for the treatment of chronic … The post BeiGene, Assembly Bio Ink $540M China HBV Deal; Shares Surge appeared first on Smarter Analyst .
Read More 'ASMB' Stories Here
ASMB Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7545 seconds.